Recommendations of the Advisory Committee on Immunization Practices for Use of Hepatitis A Vaccine for Persons Experiencing Homelessness

Documentación CAPI
Hepatitis A
Estados Unidos
Título(s) original(es)
Recommendations of the Advisory Committee on Immunization Practices for Use of Hepatitis A Vaccine for Persons Experiencing Homelessness
Autor(es)
ACIP
Topics
recomendación
Fuente(s)
CAPI - Estados Unidos
Año de publicación
2019

Descripción

What is already known about this topic?
Hepatitis A (HepA) vaccine is highly safe and effective, and a complete HepA vaccine series provides long-term protection against hepatitis A virus (HAV) infection. Person-to-person HAV outbreaks among persons using drugs or experiencing homelessness are widespread and ongoing.

What is added by this report?
All persons aged ≥1 year experiencing homelessness should be routinely immunized against HAV. Vaccination of homeless persons facilitates integration of HepA vaccine into routine preventive services.

What are the implications for public health practice?
HepA vaccination of homeless persons would improve protection of persons at increased risk of exposure to HAV and complications of hepatitis A disease and reduce the risk for large-scale outbreaks by increasing immunity to HAV among homeless persons living in congregate settings where HAV can spread readily.

Noticias y eventos relacionados

  • Estados Unidos

    ACIP releases the 2017 adult and childhood immunization schedules

    06.02.2017

    The CDC and its Advisory Committee on Immunization Practices (ACIP), together with the AAFP and other medical professional organizations, have released the 2017 adult and childhood immunization schedules.

    Leer más
  • Estados Unidos

    CDC Advisory Committee On Immunization Practices Votes To Recommend Vaxchora, PaxVax’s Single-Dose Oral Cholera Vaccine

    27.06.2016

    The ACIP voted unanimously at their June 22 meeting to recommend Vaxchora for the prevention of toxigenic Vibrio cholerae O1 for travelers to areas of active cholera transmission. The Category A recommendation made by the ACIP for Vaxchora will be forwarded to the director of the CDC and the U.S. Department of Health and Human Services for review and approval. Once approved, the recommendations will be published in the Morbidity and Mortality Weekly Report (MMWR). Category A recommendations are made for all persons in an age- or risk-factor-based group.

    Leer más
  • Estados Unidos

    ACIP recommends not to use LAIV During 2016-17 Flu Season

    24.06.2016

    The CDC's Advisory Committee on Immunization Practices (ACIP) held its meeting on June 22-23, 2016. Influenza was on the agenda and ACIP voted to recommend that live attenuated influenza vaccine (LAIV; FluMist), which is licensed for use in people ages 2-49 years, should not be used during the 2016-17 flu season.

    Leer más